ArticleScientific reports2026
Intrathecal amylin reverses morphine tolerance through site-specific DNA methylation of Pdyn and Bdnf promoters in rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic use of opioids such as morphine can lead to tolerance, opioid-induced hyperalgesia, and addiction. Amylin has demonstrated analgesic properties and the ability to reverse morphine properties when injected intrathecally in rats. Our previous study correlated these effects with reduced spinal cord Bdnf expression. To further investigate the mechanisms underlying amylin's reversal of morphine tolerance, we analyzed the mRNA expression of Pdyn and DNA methyltransferases (Dnmt3a and Dnmt3b), along with the methylation status of Pdyn and Bdnf exon IV promoters in the lumbar spinal cord of rats. Quantitative RT-PCR showed that morphine elevated Pdyn mRNA levels, an effect reversed by co-administration of amylin (1-60 pmol) between days 6 and 10 post-tolerance induction. The highest amylin dose also significantly upregulated Dnmt3a expression. Methylation-specific PCR (MSP-PCR) revealed unmethylated Pdyn and Bdnf promoters in saline-treated and morphine-only rats, but 20-100% methylation in rats treated with both morphine and amylin, and 100% methylation with amylin alone. Bisulfite sequencing confirmed site-specific methylation at CpG - 197 in the Bdnf promoter and CpG - 110 in the Pdyn promoter. These molecular changes, observed in animals with behaviorally confirmed morphine tolerance and amylin- induced reversal, suggest that amylin reverses morphine tolerance through mechanisms associated with Dnmt3a upregulation and site-specific methylation of Pdyn and Bdnf promoters, revealing a novel epigenetic correlation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.